172 related articles for article (PubMed ID: 28098838)
1. Role of UDP-Glucuronosyltransferase 1A1 in the Metabolism and Pharmacokinetics of Silymarin Flavonolignans in Patients with HCV and NAFLD.
Xie Y; Miranda SR; Hoskins JM; Hawke RL
Molecules; 2017 Jan; 22(1):. PubMed ID: 28098838
[TBL] [Abstract][Full Text] [Related]
2. Identification of UDP-glucuronosyltransferases involved in the metabolism of silymarin flavonolignans.
Vrba J; Papoušková B; Lněničková K; Kosina P; Křen V; Ulrichová J
J Pharm Biomed Anal; 2020 Jan; 178():112972. PubMed ID: 31727359
[TBL] [Abstract][Full Text] [Related]
3. Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.
Schrieber SJ; Hawke RL; Wen Z; Smith PC; Reddy KR; Wahed AS; Belle SH; Afdhal NH; Navarro VJ; Meyers CM; Doo E; Fried MW
Drug Metab Dispos; 2011 Dec; 39(12):2182-90. PubMed ID: 21865319
[TBL] [Abstract][Full Text] [Related]
4. Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2).
Miranda SR; Lee JK; Brouwer KL; Wen Z; Smith PC; Hawke RL
Drug Metab Dispos; 2008 Nov; 36(11):2219-26. PubMed ID: 18687803
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity.
Schrieber SJ; Wen Z; Vourvahis M; Smith PC; Fried MW; Kashuba AD; Hawke RL
Drug Metab Dispos; 2008 Sep; 36(9):1909-16. PubMed ID: 18566043
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract.
Wen Z; Dumas TE; Schrieber SJ; Hawke RL; Fried MW; Smith PC
Drug Metab Dispos; 2008 Jan; 36(1):65-72. PubMed ID: 17913795
[TBL] [Abstract][Full Text] [Related]
7. Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactions.
Lynch KD; Montonye ML; Tian DD; Arman T; Oyanna VO; Bechtold BJ; Graf TN; Oberlies NH; Paine MF; Clarke JD
Phytother Res; 2021 Jun; 35(6):3286-3297. PubMed ID: 33587330
[TBL] [Abstract][Full Text] [Related]
8. An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study.
Zhu HJ; Brinda BJ; Chavin KD; Bernstein HJ; Patrick KS; Markowitz JS
Drug Metab Dispos; 2013 Sep; 41(9):1679-85. PubMed ID: 23835761
[TBL] [Abstract][Full Text] [Related]
9. Evidence for differences in regioselective and stereoselective glucuronidation of silybin diastereomers from milk thistle (Silybum marianum) by human UDP-glucuronosyltransferases.
Jančová P; Siller M; Anzenbacherová E; Křen V; Anzenbacher P; Simánek V
Xenobiotica; 2011 Sep; 41(9):743-51. PubMed ID: 21524189
[TBL] [Abstract][Full Text] [Related]
10. Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects.
Bae JW; Choi CI; Lee JH; Jang CG; Chung MW; Lee SY
Eur J Clin Pharmacol; 2011 Jan; 67(1):39-45. PubMed ID: 20865252
[TBL] [Abstract][Full Text] [Related]
11. UGT1A1*28 polymorphism influences glucuronidation of bazedoxifene.
Lušin TT; Mrhar A; Trontelj J
Pharmazie; 2015 Feb; 70(2):94-6. PubMed ID: 25997248
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene glucuronidation in human intestine, kidney, and liver microsomes and in human liver microsomes genotyped for the UGT1A1*28 polymorphism.
Trdan Lusin T; Trontelj J; Mrhar A
Drug Metab Dispos; 2011 Dec; 39(12):2347-54. PubMed ID: 21937736
[TBL] [Abstract][Full Text] [Related]
13. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.
Hawke RL; Schrieber SJ; Soule TA; Wen Z; Smith PC; Reddy KR; Wahed AS; Belle SH; Afdhal NH; Navarro VJ; Berman J; Liu QY; Doo E; Fried MW;
J Clin Pharmacol; 2010 Apr; 50(4):434-49. PubMed ID: 19841158
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of rat liver UDP-glucuronosyltransferase by silymarin and the metabolite silibinin-glucuronide.
D'Andrea V; Pérez LM; Sánchez Pozzi EJ
Life Sci; 2005 Jun; 77(6):683-92. PubMed ID: 15921999
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Peer CJ; Sissung TM; Kim A; Jain L; Woo S; Gardner ER; Kirkland CT; Troutman SM; English BC; Richardson ED; Federspiel J; Venzon D; Dahut W; Kohn E; Kummar S; Yarchoan R; Giaccone G; Widemann B; Figg WD
Clin Cancer Res; 2012 Apr; 18(7):2099-107. PubMed ID: 22307138
[TBL] [Abstract][Full Text] [Related]
16. Effect of UDP-glucuronosyltransferase 1A1 activity on risk for developing Gilbert's syndrome.
Huang MJ; Chen YC; Huang YY; Yang SS; Chen PL; Huang CS
Kaohsiung J Med Sci; 2019 Jul; 35(7):432-439. PubMed ID: 31017737
[TBL] [Abstract][Full Text] [Related]
17. Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese.
Saito Y; Sai K; Maekawa K; Kaniwa N; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Ohe Y; Yamada Y; Tamura T; Yoshida T; Minami H; Ohtsu A; Matsumura Y; Saijo N; Sawada J
Drug Metab Dispos; 2009 Feb; 37(2):272-6. PubMed ID: 18981166
[TBL] [Abstract][Full Text] [Related]
18. Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms.
Erickson-Ridout KK; Sun D; Lazarus P
Pharmacogenet Genomics; 2012 Aug; 22(8):561-76. PubMed ID: 22565219
[TBL] [Abstract][Full Text] [Related]
19. Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle.
Althagafy HS; Graf TN; Sy-Cordero AA; Gufford BT; Paine MF; Wagoner J; Polyak SJ; Croatt MP; Oberlies NH
Bioorg Med Chem; 2013 Jul; 21(13):3919-26. PubMed ID: 23673225
[TBL] [Abstract][Full Text] [Related]
20. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.
Wah Kheong C; Nik Mustapha NR; Mahadeva S
Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1940-1949.e8. PubMed ID: 28419855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
